Tech Company Financing Transactions
HilleVax Funding Round
HilleVax closed a $135 million investment round on 9/9/2021. Investors included Frazier Healthcare Partners, Abingworth and BVF Partners.
Transaction Overview
Company Name
Announced On
9/9/2021
Transaction Type
Venture Equity
Amount
$135,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 State St. 100
Boston, MA 02109
USA
Boston, MA 02109
USA
Phone
Website
Email Address
Overview
HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Hershberg
Chief Financial Officer
David Socks
Chief Medical Officer
Astrid Borkowski
Chief Operating Officer
Aditya Kohli
VP - Administration
Paul Bavier
Browse more venture capital transactions:
Prev: 9/9/2021: A-Alpha Bio venture capital transaction
Next: 9/9/2021: Inpher venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs